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Introduction: 1α,25-Dihydroxyvitamin D
3
 (1,25-D
3
) is antiprolif-
erative in preclinical models of lung cancer, but in tumor tissues, its 
efficacy may be limited by CYP24A1 expression. CYP24A1 is the 
rate limiting catabolic enzyme for 1,25-D
3
 and is overexpressed in 
human lung adenocarcinoma (AC) by unknown mechanisms.
Methods: The DNA methylation status of CYP24A1 was determined 
by bisulfite DNA pyrosequencing in a panel of 30 lung cell lines and 
90 surgically resected lung AC. The level of CYP24A1 methylation 
was correlated with CYP24A1 expression in lung AC cell lines and 
tumors. In addition, histone modifications were assessed by quan-
titative chromatin immunoprecipitation–polymerase chain reaction 
(ChIP-qPCR) in A549, NCI-H460, and SK-LU-1.
Results: Bisulfite DNA pyrosequencing analysis revealed that 
CYP24A1 gene was heterogeneously methylated in lung AC. 
Expression of CYP24A1 was inversely correlated with promoter 
DNA methylation in lung AC cell lines and tumors. Treatment with 
5-aza-2′-deoxycytidine (5-Aza) and trichostatin A (TSA) increased 
CYP24A1 expression in lung AC. We observed that CYP24A1 pro-
moter hypermethylation decreased CYP24A1 enzyme activity in 
vitro, whereas treatment with 5-Aza and/or TSA increased CYP24A1 
enzyme affinity for its substrate 1,25-D
3
. In addition, ChIP-qPCR 
analysis revealed specific histone modifications within the CYP24A1 
promoter region. Treatment with TSA increased H3K4me2 and 
H3K9ac and simultaneously decreased H3K9me2 at the CYP24A1 
promoter and treatment with 5-Aza and/or TSA increased the recruit-
ment of vitamin D receptor (VDR) to vitamin D response elements 
(VDRE) of the CYP24A1 promoter.
Conclusions: The expression of CYP24A1 gene in human lung AC 
is in part epigenetically regulated by promoter DNA methylation and 
repressive histone modifications. These findings should be taken into 
consideration when targeting CYP24A1 to optimize antiproliferative 
effects of 1,25-D
3
 in lung AC.
Key Words: Vitamin D metabolism, CYP24A1, 
 1α,25-Dihydroxyvitamin-D
3
, DNA methylation, Histone modifica-
tion, Lung adenocarcinoma.
(J Thorac Oncol. 2014;9: 473–482)
1α,25-Dihydroxyvitamin D3 (1,25-D3, calcitriol) is the most active form of vitamin D and has antineoplastic activ-
ity at supraphysiologic doses in several cancers both in vitro 
and in vivo.1 At these doses, 1,25-D
3
 is associated with anti-
proliferative activity,2–4 induction of cell differentiation,5 cell 
cycle arrest,6 apoptosis,7,8 and inhibition of angiogenesis.9 
Antiproliferative activity is mediated through the vitamin D 
receptor (VDR), which is not only found in classic target organs 
(intestinal tract, kidney and bone) but also in many other epi-
thelial and mesenchymal cells of tissues, such as lung, pros-
tate, and breast. The evidence for a possible role of the vitamin 
D pathway in lung cancer comes largely from in vitro or in 
vivo studies. Higashimoto et al.10 reported that 1,25-D
3
 inhib-
ited the growth of lung cancer cell lines and affects cell cycle 
regulation in squamous cell carcinoma models.11,12 1,25-D
3
 has 
been shown to inhibit lung tumor growth and lung metastases 
in mouse models.13,14 The antiproliferative effect of 1,25-D
3
 is 
related to G
1
 cell cycle arrest and is directly and inversely pro-
portional to the VDR15 and CYP24A1 expression, respectively.16
CYP24A1 is a member of the cytochrome P450 super-
family of enzymes involved in drug metabolism and syn-
thesis of steroids and other lipids. CYP24A1 encodes for 
 24-hydroxylase, the rate limiting enzyme that catalyzes the 
inactivation of 1,25-D
3
. This gene is located on chromosome 
20q13.2 and is thought to be a proto-oncogene. Albertson 
et al.17 reported that gene copy number and CYP24A1 
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expression are increased in breast cancer. Mimori et al.18 
correlated overexpression of CYP24A1 and poor survival in 
esophageal cancer. We and others16,19,20 have reported up-reg-
ulation of CYP24A1 in non–small-cell lung cancer as com-
pared with normal tissues. Furthermore, overexpression of 
CYP24A1 resulted in increased catabolism of 1,25-D
3
 in lung 
cancer cells compared with nonneoplastic lung.21 Our initial 
studies revealed that CYP24A1 messenger RNA (mRNA) was 
significantly overexpressed (8- to 50-fold) in lung adenocar-
cinoma (AC) as compared with nonneoplastic lung tissue and 
especially higher in poorly differentiated tumors. In addition, 
resected lung AC patients with CYP24A1 overexpression had 
significantly shorter overall survival (OS) as compared with 
those with low CYP24A1 (5-year survival rate, 42% versus 
81%, respectively; Log-rank p = 0.007).16 In this study, we 
found that one-third of patients with high CYP24A1 expres-
sion showed gain in region of 20q, even though focal amplifi-
cation was only noted in a small percentage of the tumors. We 
hypothesized that epigenetic mechanisms such as promoter 
methylation and histone modifications may be involved in the 
transcriptional regulation of CYP24A1. CYP24A1 has a pro-
moter region that is rich in CpG islands, and tissue-specific 
CYP24A1 promoter hypermethylation has been described in 
normal human tissues.22 Interestingly, transformed neoplas-
tic cells have also demonstrated differential methylation of 
the CYP24A1 gene. Luo et al.23 showed that CYP24A1 gene 
expression in human prostate cancer is silenced in part by pro-
moter DNA methylation and repressive histone modifications.
In this study, we sought to determine whether epigen-
etic regulation of the CYP24A1 gene in lung AC could explain 
its differential expression in lung AC and whether these 
events result in differential affinity to the substrate 1,25-D
3
. 
Considering the importance of CYP24A1 in the regulation of 
1,25-D
3
 levels, we elucidated the roles of DNA methylation 
and histone modification of CYP24A1 in human lung AC cell 
lines and primary lung AC.
MATERIALS AND METHODS
Human Samples
Lung tumor samples were obtained from patients 
undergoing primary thoracic resection for lung cancer with-
out preoperative radiation or chemotherapy, as previously 
described.24 Tissue specimens were banked with informed 
consent after approval from the University of Michigan 
Institutional Review Board and Ethics Committee and were 
frozen in liquid nitrogen and stored at –80°C. Percentage of 
tumor purity in sections adjacent to the regions used for RNA 
extraction was estimated during routine histopathologic anal-
ysis. Regions containing a minimum of 70% tumor cellularity 
were utilized for DNA and RNA isolation.
Bisulfite DNA Pyrosequencing Analysis
Genomic DNA was isolated using the genomic DNA 
isolation kit (Qiagen, Valencia, CA). DNA (500 ng) was con-
verted using the EZ DNA Methylation Kit (Zymo Research 
Corp., Irvine, CA), following manufacturers’ recommenda-
tions. Methylation status of the CYP24A1 promoter in human 
lung primary tissue samples and cell lines was assessed through 
pyrosequencing assay. Bisulfite pyrosequencing assays for 
the CYP24A1 gene were designed to assess the methylation 
status of five CpG sites corresponding to the 3′-CpG island, 
while spanning a putative regulatory sequence located in exon 
1 within this CpG island. The sequences of the primers used 
for polymerase chain reaction (PCR) amplification were +66F 
(5′-GGAAAAGGAAGTAAAGAGGGTTAGT-3′) and +301R 
 (Biotin-5′-ACCAAACCCTAAAAATCAACCTTAC-3′), and the 
sequencing primer was 5′-TTAGTGTAAGGAGGTATTAA-3′. 
PCR cycling conditions were as follows: initial incubation at 
95°C for 5 minutes, followed by 45 cycles of 95°C for 30 seconds, 
57°C for 30 seconds, and 72°C for 30 seconds. Pyrosequencing 
reactions were performed in a PSQ 96 Pyrosequencing System 
(Biotage, Charlotte, NC) using appropriate reagents and proto-
cols. The analysis was performed in duplicate in two independent 
experiments, and methylation value was obtained from the aver-
age of each of the five CpG sites included in the sequence ana-
lyzed. Controls to assess accurate bisulfite conversion of the DNA 
were used on each run to ensure the fidelity of the measurements.
Cell Culture
Three human lung AC cancer cell lines (A549,  NCI-H460, 
and SK-LU-1) were obtained from American Type Culture 
Collection (Manassas, VA) and cultured with Roswell Park 
Memorial Institute Medium (RPMI) 1640 or Dulbecco's Modified 
Eagle’s Medium (DMEM)-F12 medium (Invitrogen, Carlsbad, 
CA) with 10% fetal bovine serum (Hyclon, Logan, UT) and 1% 
Gibco Antibiotic-Antimycotic (Life Technologies, Carlsbad, CA) 
at 37°C in a humid atmosphere consisting of 5% carbon diox-
ide/95% air. Cell lines were authenticated and genotyped using 
the Identifiler Plus kit (Applied Biosystems, Carlsbad, CA).
Drug Treatments
A549, NCI-H460, and SK-LU-1 cells were seeded at 
1 × 105 cells in a six-well plate overnight. For dose–response 
effects, cells were treated with 5-aza-2′-deoxycytidine (5-Aza, 
Sigma–Aldrich, St. Louis, MO) at concentrations of 0.1, 0.5, 
1.2, and 5 μM for 72 hours, followed by an additional incuba-
tion for 24 hours with or without 100 nM of 1,25-D
3
 (Sigma–
Aldrich), and then were finally harvested. Cells were also 
treated with trichostatin A (TSA; Sigma–Aldrich) at 50, 100, 
200, 300, and 400 nM for 8 hours, followed by an additional 
incubation for 24 hours with or without 1,25-D
3
 (100 nM), and 
then harvested. For 5-Aza and TSA combination treatments, 
cells were treated with 5 μM of 5-Aza for 72 hours, followed 
by addition of 300 nM of TSA and 100 nM of 1,25-D
3
 for an 
additional 24 hours, and then harvested.
RNA Extraction and Complementary 
DNA Synthesis
Total RNA was isolated from the tissue samples and cell 
lines using Trizol (Invitrogen) followed by column purification 
using the RNeasy Mini kit (Qiagen) according to the manu-
facturers’ instructions. RNA was eluted from the spin column 
using RNase-free dH
2
O. Complementary DNA (cDNA) was 
prepared from RNA samples using the High Capacity cDNA 
475Copyright © 2014 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 9, Number 4, April 2014 Epigenetic Regulation of Vitamin D Metabolism
Reverse Transcription kit (Applied Biosystems, Foster City, 
CA) according to manufacturer’s protocols.
Quantitative Real-Time Reverse 
Transcription PCR
The quantitative real-time reverse transcription PCR 
 (qRT-PCR) reaction was prepared using Power SYBR 
Green Master Mix (Applied Biosystems), and qRT-PCR 
was performed with the StepOne Real-Time PCR System 
(Applied Biosystems). Each sample had a final volume 
of 15 μl containing approximately 100 ng of cDNA. The 
sequences of the oligonucleotide primers for CYP24A1 
(144 base pair [bp] PCR product) were as follows: 
5′-GCCGTATTTAAAAGCCTGTCTGAA-3′ (forward) and 
5′-ACCTGGGTATTTAGCATGAGCACTG-3′ (reverse). 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was 
used to standardize the CYP24A1 qRT-PCR results. Relative 
mRNA levels were assessed using the 2−∆∆Ct method as 
described previously.16
CYP24A1 Activity Assay
Cells were treated with 5 μM of 5-Aza for 72 hours 
and/or 300 nM of TSA for 8 hours and were washed with 
phosphate-buffered saline twice. The cells (5 × 105) were then 
incubated with 1,25-D
3
 (100 nM) in 3 ml of medium for 48 
hours. The medium was collected and the cells were treated 
with lysis buffer and were combined with the medium. The 
remaining 1,25-D
3
 in the combined medium and cell lysate 
was analyzed using the 1,25-Dihydroxy Vitamin D EIA kit 
(Immunodiagnostic Systems Ltd., Scottsdale, AZ) according 
to the manufacturer’s instruction.
Quantitative Chromatin 
Immunoprecipitation-PCR
Quantitative chromatin immunoprecipitation–PCR 
(ChIP-qPCR) was performed essentially as described by 
Väisänen et al.25 Briefly, cells were treated with 5-Aza (5 μM) 
or TSA (300 nM) or both agents. One hour after adding 1,25-
D
3
, the cells were fixed by adding formaldehyde as described 
previously to cross-link nuclear protein to DNA. Chromatin 
was sheared enzymatically (Active Motif, Carlsbad, CA) to 
approximately 500 bp on an average length and was precipitated 
with the antibodies against H3K9me2, H3K4me2, H3K9ac, 
and VDR. Antibodies against H3K9me2, H3K4me2, and 
H3K9ac were purchased from Active Motif, and an antibody 
against VDR was obtained from Santa Cruz Biotechnologies 
(Dallas, TX). ChIP reaction was performed two times. ChIP-
qPCR primers for the CYP24A1 promoter region 1 and 
region 2 were −292F (5′-AGCACACCCGGTGAACTC-3′) 
and −152R (5′-TGGAAGGAGGATGGAGTCAG-3′); 
+130F (5′-TTCAAGAGGTCCCCAGACAC-3′) and +333R 
(5′-AGTCGGGGCTTAACGATTCT-3′). ChIP-qPCR was 
performed using the Power SYBR Green PCR Master Mix 
(Applied Biosystems) with the following reaction cycling: 
95°C for 10 minutes, 45 cycles of 94°C for 30 seconds, and 
57°C for 30 seconds.23 ChIP-qPCR was run in triplicate 
and repeated twice per each ChIP reaction to confirm the 
reproducibility of results. Copy number was determined using 
a standard curve containing serial dilutions (107–100 copies) of 
the CYP24A1 DNA amplicon. Results were normalized to 10% 
input DNA amplifications after subtraction of signals obtained 
from the antibody isotype control.
Protein Isolation and Immunoblot Analysis
A549, NCI-H460, and SK-LU-1 cells were plated and 
grown until 80% confluent. The cells were harvested with lysis 
buffer26 (150 mM NaCl, 20 mM Tris [pH 7.5], 1 mM ethylene-
diaminetetraacetic acid, 1 mM EGTA, 2.5 mM Na
4
P
2
O
7
, 1 mM 
β-glycerol 2-phosphate disodium salt hydrate, 1 mM Na
3
VO
4
, 
1% Triton X-100) supplemented with protease inhibitor 
cocktail (Sigma–Aldrich). Proteins were quantified using the 
 Bio-Rad protein assay kit (Bio-Rad Laboratories, Hercules, 
CA) according to the manufacturer’s protocol. Proteins (20 
μg) were resolved on 10% tris-glycine gels (Invitrogen) and 
transferred to nitrocellulose membranes (Pall Corp., Ann 
Arbor, MI). The blots were probed with either anti-CYP24A1 
(Santa Cruz Biotechnology), anti-DNA methyltransferase 
(DNMT) 1 (Cell Signaling Biotechnology, Beverly, CA), and 
anti-DNMT3A (Cell Signaling Biotechnology) diluted at 
1:1000, or GAPDH (Calbiochem; EMD Bioscience Inc., San 
Diego, CA) diluted at 1:10,000. GAPDH was used as a load-
ing control. Each band was normalized by GAPDH. Arbitrary 
units in the figures represent the ratio between the normal-
ized band density of the specific protein treated with 5-Aza 
and/or TSA and the corresponding untreated protein. This was 
repeated in three independent experiments.
Statistical Analysis
Chi-square and posteriori analysis of variance (ANOVA) 
tests were used to identify statistically significant differences 
between different clinical variables and the level of CYP24A1 
methylation. The significance of differences between in vitro 
experimental conditions was determined using the ANOVA 
tests, and p value of less than 0.05 was considered significant. 
The outcome variables for survival analysis were disease-free 
survival (DFS) and OS. DFS was measured from the date 
of surgery to the time of recurrence, death, or censoring at 
5 years. OS was measured from date of surgery to the time 
of death or censoring at 5 years. Survival curves were con-
structed using the method of Kaplan–Meier, and survival dif-
ferences were assessed using the Log-rank test. The univariate 
and multivariate Cox proportional hazards model including 
the covariates of age, sex, smoking history, disease stage, and 
adjuvant treatment were used for assessing the prognostic 
value of CYP24A1 methylation on DFS and OS. The Pearson’s 
method was used to test the correlation between CYP24A1 
expression and CYP24A1 promoter DNA methylation.
RESULTS
CYP24A1 Promoter Methylation in Lung 
Cell Lines and Lung AC Tumors
We used bisulfite DNA pyrosequencing assays to determine 
the methylation status of CYP24A1 in a panel of 27 lung cancer cell 
lines, three immortalized lung cell lines, and 90 lung AC tumors. 
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Based on the National Center for Biotechnology Information 
(NCBI) Epigenomics database27 the human CYP24A1 gene con-
tains two CpG islands (580 and 1231 bp, respectively) that span 
its transcription start site.28 Interestingly, the 5′-CpG island of the 
CYP24A1 gene encompasses the promoter region and contains 
two known vitamin D response elements (VDREs): the proximal 
element VDRE (VDREp) (−172/−143) and the distal element 
VDRE (VDREd) (−293/−273).29 We assessed the methylation 
status of the 3′-CpG island, since it was previously reported that 
this region undergoes higher levels of DNA methylation.23 The 
3′-CpG island of CYP24A1 was heterogeneously methylated 
among the 30 lung cancer cell lines and lung AC tumors (Fig. 
1A and B). Using a 10% cutoff, 20 cell lines (66.7%) and 32 
primary tumors (35.5%) harbored CYP24A1 hypermethylation. 
Using DNA methylation array data from a previous study,30 
we observed that nonmalignant lung samples had significantly 
higher β-value at multiple CpG sites located at CYP24A1 pro-
moter (Supplementary Fig. 1, Supplementary Digital Content, 
http://links.lww.com/JTO/A535).
Next, we assessed the correlation between CYP24A1 
mRNA expression and CYP24A1 promoter DNA methylation 
in a subset of 16 lung cancer cell lines expressing variable lev-
els of CYP24A1 and the same cohort of 90 lung AC tumors. We 
found a statistically significant negative correlation between 
CYP24A1 expression and methylation in the lung cancer cell 
lines (r = −0.53, p = 0.031, Fig. 1C) and in the lung AC tumors 
(r = −0.28, p = 0.008, Fig. 1D), suggesting that DNA meth-
ylation plays an important role in the regulation of CYP24A1 
expression. Nevertheless, we observed some tumors and cell 
lines with low CYP24A1 methylation expressed low lev-
els of CYP24A1, suggesting that other mechanisms such as 
copy number or posttranslational modifications might also be 
involved in CYP24A1 regulation.
CYP24A1 Promoter Methylation Is Associated 
with Clinical Outcome in Lung AC
The correlation between the clinicopathological variables 
and the level of CYP24A1 methylation was assessed and is 
shown in Table 1. No statistically significant differences were 
observed according to age, sex, smoking history, tumor dif-
ferentiation, disease stage, and adjuvant treatment. Although 
smokers had a significantly higher CYP24A1 expression 
(n = 80; mean, 16.91; SE, 2.61) as compared with nonsmokers 
(n = 10; mean, 5.87; SE, 3.43; t test p = 0.018), no significant 
differences were observed in the CYP24A1 methylation sta-
tus according to the tobacco history. Interestingly, unmethyl-
ated CYP24A1 was associated with higher proportion of death 
(p = 0.076) and recurrence (p = 0.039). Survival analysis accord-
ing to the level of CYP24A1 methylation revealed that patients 
with unmethylated CYP24A1 had significantly worse DFS (Log-
rank p = 0.018, Fig. 2A) and OS (Log-rank p = 0.038, Fig. 2B).
The statistically significant clinical variables in the uni-
variate Cox regression for DFS and OS were included in the 
multivariate Cox analysis (disease stage, adjuvant treatment, 
and smoking history). Remarkably, unmethylated CYP24A1 
was associated with worse DFS (hazard ratio = 2.55; 95% 
confidence interval, 1.17–5.58; p = 0.019) and OS (hazard 
ratio = 2.65; 95% confidence interval, 1.11–6.37; p = 0.029) 
in the multivariate analysis. These results imply that CYP24A1 
unmethylation might be an independent prognostic marker in 
lung AC and are consistent with our previous findings where 
CYP24A1 overexpression was associated with poor outcome 
in lung AC patients.16
Effects of Epigenetic Regulation of CYP24A1 
Gene Expression in Lung AC Cells
To determine the effect of CYP24A1 promoter methyla-
tion in CYP24A1 gene expression, three lung AC cells (A549, 
NCI-H460, and SK-LU-1) with various levels of CYP24A1 
methylation and expression were treated with 5-Aza, a DNMT 
inhibitor, or TSA, a histone deacetylase inhibitor. qRT-PCR 
revealed an up-regulation of CYP24A1 gene expression in 
NCI-H460 and SK-LU-1 cells when treated with 5-Aza or 
TSA in combination with 1,25-D
3
 (Fig. 3A). In contrast, A549, 
which has an unmethylated CYP24A1 CpG promoter, showed 
no increase in CYP24A1 expression with 5-Aza and/or TSA 
treatment (Fig. 3A). Restoration of CYP24A1 mRNA expres-
sion by 5-Aza and TSA was dose dependent in  NCI-H460 and 
SK-LU-1 (Supplementary Fig. 2A, Supplementary Digital 
Content, http://links.lww.com/JTO/A535). Consistent with 
the activation of CYP24A1 mRNA expression by 5-Aza, TSA, 
or both drugs induced CYP24A1 protein expression in NCI-
H460 and SK-LU-1 cells as well (Fig. 3B). Nevertheless, 
combination treatment with 5-Aza and TSA did not induce 
a significant increase in CYP24A1 mRNA (Fig. 3A) or 
CYP24A1 protein (Fig. 3B) expression in these cells.
To determine whether DNMTs play a key role in the reg-
ulation of CYP24A1 DNA promoter methylation, we analyzed 
DNMT1 and DNMT3A protein expression in A549, NCI-
H460, and SK-LU-1 cells with 5-Aza and/or TSA treatment 
(Fig. 3B). Western blot analysis revealed that the basal expres-
sion levels of DNMT1 and DNMT3A were higher in NCI-H460 
and SK-LU-1 cells compared with A549 cells (Supplementary 
Fig. 2B, Supplementary Digital Content, http://links.lww.com/
JTO/A535). DNMT1 was inhibited by 5-Aza in A549 and NCI-
H460 cells but not in SK-LU-1 cells, whereas DNMT3A was 
inhibited by 5-Aza in all three cells (Fig. 3B).
To confirm whether increased CYP24A1 expression by 
5-Aza or TSA led to increased CYP24A1 activity, CYP24A1 
enzyme activity assay was performed. CYP24A1 enzyme activ-
ity was significantly increased in SK-LU-1 cells treated with 
5-Aza, TSA, or both (Fig. 3C). In A549 cells, no significant 
increase in enzyme activity was observed when treated with 
5-Aza alone, but the combination of 5-Aza with TSA led to 
a significant increase of CYP24A1 enzyme activity (Fig. 3C).
Histone Modifications at the CYP24A1 Promoter
To investigate the role of histone modifications in 
the regulation of CYP24A1 gene, the active histone marks 
(H3K4me2 and H3K9ac) and the repressive histone mark 
(H3K9me2) associated with the CYP24A1 promoter region 
were assessed using ChIP-qPCR. CYP24A1 mRNA and pro-
tein is not expressed in SK-LU-1 cells, which have high level 
of CYP24A1 promoter hypermethylation (56.3%) and showed 
relatively high level of the repressive histone mark (H3K9me2) 
as compared with A549 and NCI-H460 (Fig. 4A). Surprisingly, 
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the active histone markers (H3K4me2 and H3K9ac) were also 
relatively high in SK-LU-1 as compared with the other cells. 
NCI-H460 cells that express low CYP24A1 which is hyper-
methylated (19.3%) showed the lowest levels of active histone 
marks (H3K4me2 and H3K9ac) relative to the other cells 
(Fig. 4A). In addition, we observed that the profile of his-
tone marks at the CYP24A1 promoter was modified by treat-
ing SK-LU-1 and NCI-H460 cells with 5-Aza and/or TSA 
(Fig. 4B and C). In SK-LU-1 cells, the ChIP-qPCR assay 
showed that 5-Aza, TSA, or both significantly increased 
H3K9ac and H3K4me2 levels and decreased H3K9me2 level 
(Fig. 4B). Similar histone changes were observed in NCI-H460 
cells after treatment with 5-Aza and/or TSA as well (Fig. 4C).
Binding of VDR to the CYP24A1 Promoter 
by Epigenetic Modulatory Drugs
To confirm whether these epigenetic changes induced 
by 5-Aza and/or TSA may affect the binding of VDR to the 
CYP24A1 promoter region, ChIP-qPCR analysis was per-
formed using a VDR-specific antibody. A significant increase 
in VDR binding to the CYP24A1 promoter was detected in 
NCI-H460 (Fig. 5A) and SK-LU-1 cells (Fig. 5B) upon treat-
ment with 5-Aza and TSA, in addition to 1,25-D
3
. These data 
support that decreased recruitment of VDR to the CYP24A1 
promoter in NCI-H460 and SK-LU-1 cells, due to hypermeth-
ylation and repressive histone modifications, result in the sup-
pression of CYP24A1 expression in lung cancer cells.
DISCUSSION
There has been increasing interest in incorporating 
1,25-D
3
 in cancer therapy and for prevention. Nevertheless, 
before designing large clinical trials, it is imperative to under-
stand the pharmacokinetics and pharmacodynamic properties 
of 1,25-D
3
. It seems that the metabolism of 1,25-D
3
 might 
be strongly influenced by tissue context. In particular, both 
CYP27B1 (enzyme that converts 25(OH)-D
3
 to 1,25-D
3
) and 
FIGURE 1. CYP24A1 promoter DNA methylation in lung cancer cell lines and primary lung AC. Bisulfite pyrosequencing 
analysis covering five CpG sites of the CYP24A1 promoter in 27 lung cancer cell lines and three lung immortalized lines (A) and 
90 lung AC tumors (B). The average methylation percentage from five CpGs was used for calculating the total proportion of 
methylated CpGs in the CYP24A1 promoter region. Scatterplot of CYP24A1 messenger RNA expression and CYP24A1 promoter 
methylation in a subset of 16 lung cancer cell lines (C) and 90 lung AC (D). An inverse correlation among CYP24A1 expression 
and methylation was found in lung cancer cell lines and lung AC tumors. AC, adenocarcinoma.
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CYP24A1 (rate limiting enzyme that converts 1,25-D
3
 to 
inactive metabolite) lend themselves to epigenetic regulation. 
Several studies have suggested a differential epigenetic regu-
lation in normal versus neoplastic cells.31–33 Our study focuses 
on the epigenetic regulation of CYP24A1 in lung AC, where 
there is a differential expression of CYP24A1 mRNA.16 In this 
study, we demonstrate that DNA methylation of CYP24A1 
gene is a plausible molecular mechanism for down-regulation 
TABLE 1.  Correlation Between Clinicopathological Characteristics and CYP24A1 DNA Methylation Levels Categorized as 
Unmethylated (<25 percentile, <5.7%), Low Methylation (25–75 percentile, 5.7%–12.9%), and High Methylation  
(>75 percentile, >12.9%)
Characteristics
Nonmethylated 
(n = 22)
Low Methylation 
(n = 46)
High Methylation 
(n = 22)
All Patients 
(n = 90) p
Age (yr)
  Mean (SD) 66.2 (±9.9) 67.4 (±9.9) 67.8 (±9.7) 67.2 (±9.7) 0.851
Sex, n (%)
  Male 15 (68) 22 (48) 8 (36) 45 (50)
  Female 7 (32) 24 (52) 14 (64) 45 (50) 0.099
Smoking, n (%)
  Never smokers 1 (4.5) 8 (17) 1 (4.5) 10 (11)
  Smokers (<35 PY) 8 (36.5) 18 (39) 8 (36.5) 34 (38)
  Smokers (≥35 PY) 13 (59) 20 (43) 13 (59) 46 (51) 0.348
Stage, n (%)
  I 10 (45) 25 (54) 10 (46) 45 (50)
  II 6 (27) 10 (22) 8 (36) 24 (27)
  III 3 (14) 8 (17) 4 (18) 15 (17)
  IV 3 (14) 3 (7) 0 (0) 6 (7) 0.571
Differentiation, n (%)
  Well 6 (27) 12 (26) 5 (23) 23 (26)
  Moderate 6 (27) 15 (33) 12 (54) 33 (37)
  Poor 10 (46) 19 (41) 5 (23) 34 (38) 0.335
Adjuvant treatment, n (%)
  Yes 9 (41) 14 (31) 8 (36) 31 (35)
  No 13 (59) 31 (69) 14 (64) 58 (65) 0.721
Life status, n (%)
  Dead 15 (68) 20 (43.5) 8 (36) 43 (48)
  Alive 7 (32) 26 (56.5) 14 (64) 47 (52) 0.076
Recurrence, n (%)
  Yes 13 (62) 14 (30) 11 (50) 38 (43)
  No 8 (38) 32 (70) 11 (50) 51 (57) 0.039
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FIGURE 2.  Kaplan–Meier plot of DFS and OS according to level of CYP24A1 methylation. A, Patients with unmethylated CYP24A1  
(n = 22) had significantly median shorter DFS (16.8; 95% CI, 8.9–24.6) as compared with low and high CYP24A1 methylation  
(n = 46 and 22, 56.5 and median not reached, respectively, Log-rank p = 0.018). B, Patients with unmethylated CYP24A1 (n = 22)  
had significantly median shorter OS (25.3, 95% CI, 12.9–37.7) as compared with low and high CYP24A1 methylation (n = 46  
and 22, respectively, median not reached, Log-rank p = 0.038). DFS, disease-free survival; OS, overall survival; CI, confidence 
interval.
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of CYP24A1 gene expression in human lung cancer based on 
the following observations from our study results. An inverse 
correlation was found between CYP24A1 expression and pro-
moter hypermethylation in lung AC cell lines and primary 
tumors. In addition, CYP24A1 expression was restored when 
lung cell lines endogenously expressing low CYP24A1 were 
treated with the demethylating agent (5-Aza). Accordingly, 
when the unmethylated and high CYP24A1 expressing 
cells (A549) were treated with 5-Aza, CYP24A1 expression 
remained unchanged. Evidence in the current study and previ-
ous reports22,32–34 supports the role of promoter DNA hyper-
methylation in inducing CYP24A1 silencing.
We found that lung AC patients with unmethylated 
CYP24A1 promoter had significantly worse DFS and OS, 
independently of other clinical covariates, such as disease 
stage, smoking status, and adjuvant therapy. These results are 
consistent with our previous study that reported that CYP24A1 
overexpression was associated with poor outcome for patients 
with resected lung AC, and further validation using an inde-
pendent cohort is warranted.
Histone modifications could provide an alternative 
regulatory mechanism that affects CYP24A1 gene expres-
sion in vitro and in vivo.35–37 Previous studies have shown 
that hypermethylated promoters often involve recruitment 
of  methyl-binding domain proteins and histone-modifying 
enzymes such as histone deacetylases.38–41 Indeed, lower 
expression of CYP24A1 observed in nonsmokers is not fully 
explained by DNA methylation, since the differences in the 
CYP24A1 methylation level were not statistically significant 
between smokers and nonsmokers. ChIP-qPCR showed that 
H3K9me2, a repressive histone modification, was signifi-
cantly higher in SK-LU-1 cells. When SK-LU-1 cells were 
treated with 5-Aza and/or TSA, the recruitment of VDR on 
the CYP24A1 promoter was increased, resulting in a higher 
CYP24A1 mRNA expression as well. Previous studies sup-
port our findings that hypermethylation of these regions could 
lead to a chromatin state in which the VDR is prevented from 
binding to the VDREs in the CYP24A1 promoter, resulting 
in transcriptional silencing of CYP24A1.23 In contrast, low 
H3K9me2 (repressive histone modification) in A549 cells, 
C
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FIGURE 3.  Restoration of CYP24A1 gene expression and protein expression by 5 μM of 5-Aza or 300 nM of TSA treatment 
followed by 100 nM of 1,25-D3 in lung adenocarcinoma cells. A, Quantitative real-time reverse transcription polymerase chain 
reaction of CYP24A1 expression in A549, NCI-H460, and SK-LU-1 lung cancer cells treated with 5-Aza (5A), TSA (T), and 5-Aza 
plus TSA (5A/T) followed by 1,25-D3. B, Western blot analysis of CYP24A1, DNMT1, and DNMT3A protein expression in A549, 
NCI-H460, and SK-LU-1 cells treated with 5-Aza (5A), TSA (T), and 5-Aza plus TSA (5A/T) followed by 1,25-D3. GAPDH was 
used as loading control. C, CYP24A1 enzymatic activity in A549, NCI-H460, and SK-LU-1 lung cancer cells treated with 5-Aza 
(5A), TSA (T), and 5-Aza plus TSA (5A/T) followed by 1,25-D3. Bar plots and error bars represent mean and standard deviation 
of triplicate data points. *p value < 0.05; **p < 0.01;***p < 0.001. 5-Aza, 5-aza-2′-deoxycytidine; TSA, trichostatin A; 1,25-D3, 
 1α,25-dihydroxyvitamin D3; DNMT, DNA methyltransferase; GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
480 Copyright © 2014 by the International Association for the Study of Lung Cancer
Ramnath et al. Journal of Thoracic Oncology ®  •  Volume 9, Number 4, April 2014
which have the highest CYP24A1 expression, suggests an 
association of an open chromatin structure with active gene 
expression.42,43
These data are consistent with the hypothesis that 
aberrant DNA methylation and repressive histone modifica-
tions function in combination to silence important genes in 
human cancers.23,44–46 In colon cancer, however, the CYP24A1 
gene is also reactivated by methyltransferase inhibitor in a 
 cell-line-dependent manner, and this effect does not corre-
late with the methylation state of the promoter, suggesting 
that other genes located upstream of CYP24A1 may affect the 
methylation status of CYP24A1.47
Collectively, our findings support that CYP24A1 pro-
moter DNA hypermethylation and histone modifications are 
key mechanisms regulating CYP24A1 expression in human 
lung AC. Transcriptional silencing of the CYP24A1 gene, 
resulting from hypermethylation and/or repressive histones, 
would be advantageous to 1,25-D
3
 antiproliferative effects 
in lung cancer, whereas CYP24A1 promoter hypomethyl-
ation associated with higher mRNA expression would lead 
to increased metabolism of 1,25-D
3
. Patients with CYP24A1 
promoter hypomethylation may potentially be benefitted by a 
micronutrient diet rich in methyl donors, earlier in the patho-
genesis of lung cancer.48 Indeed, genome-wide DNA hypo-
methylation coupled with genome instability are the earliest 
events to occur in the genesis of cancer.49,50 Taken together, the 
observation from this study gives us an insight regarding the 
mechanisms regulating CYP24A1 gene expression in lung AC 
tissues, and this could facilitate the development of strategies 
to optimize vitamin D-based therapies for lung cancer.
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combination of both (5A/T) followed by 100 nM of 1α,25-dihydroxyvitamin D3. The data from immunoprecipitated DNA were 
normalized to 10% DNA input. Bar plots and error bars represent mean and standard deviation of triplicate data points. *p 
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